RT Journal Article
SR Electronic
T1 Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 7389
OP 7393
VO 34
IS 12
A1 TAMARI, KEISUKE
A1 ISOHASHI, FUMIAKI
A1 AKINO, YUICHI
A1 SUZUKI, OSAMU
A1 SEO, YUJI
A1 YOSHIOKA, YASUO
A1 HAYASHI, YOSHITO
A1 NISHIDA, TSUTOMU
A1 TAKEHARA, TETSUO
A1 MORI, MASAKI
A1 DOKI, YUICHIRO
A1 OGAWA, KAZUHIKO
YR 2014
UL http://ar.iiarjournals.org/content/34/12/7389.abstract
AB Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥41.6%, age ≥66 years, body mass index (BMI) ≥19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.